Programs
| Disorder Type | Disorder | Patent & PCT Submitted | Clinical & Epid. Studies | Pathway Characterization | Current Status |
|---|---|---|---|---|---|
| CNS | 1001 – Early Autism Detection | ✔️ | ✔️ | ✔️ | FDA Breakthrough Designation granted |
| CNS | 1002 – Attention Deficit Hyperactive Disorder | ✔️ | ✔️ | ➖ | Enrollment ongoing |
| CNS | 1003 — Psychosis & schizophrenia | ✔️ | ✔️ | ➖ | Enrollment ongoing |
| CNS | 1004 – Lou Gehrig’s Disease | ✔️ | ✔️ | ✔️ | FDA submission Q2 2022 |
| Gut | IBS, Eosinophilic Esophagitis, Microbiome | ✔️ | ➖ | ➖ | Enrollment ongoing |
| Cancer | Pediatric Cancer | ✔️ | ➖ | ➖ | Enrollment ongoing |
| Data Science | Global biodynamics dataset | ✔️ | ✔️ | ✔️ | Prototype complete |
Expertise
LinusBio Precision Exposome Medicine Program Follows the evolving precision medicine paradigm:
- Patient group stratification, disease & patient phenotyping
- Biomarker & diagnostics, patient-journey monitoring
- Characterization of pathways and biological mechanisms for target discovery
- Drug development and clinical-trial design
near-future deliverables for neurodevelopmental disease:
- First-in-class StrandDx™-ASD biomarker & diagnostic for autism.
- FDA Breakthrough Designation for ASD, awarded.
- Market access & reimbursement program for deNovo in vitro diagnostic.
milestone collaborations achieved on two fronts:
- ASD pharmaceutical / clinical trials for older ASD patients
- Non-pharmaceutical / nutraceuticals for high-risk ASD infants
Next breakthrough programs:
- Amyotrophic lateral sclerosis (ALS)
- Inflammatory bowel disease (IBD)
- Attention deficit hyperactive disorder (ADHD)
- Psychosis/schizophrenia
- Renal disease
- Pediatric cancer
